Zurück
www.reuters.com/article/idUSFWN1EG0EI
Top-News
Calithera Biosciences Reboundkanditat?
Beiträge: 59
Zugriffe: 17.687 / Heute: 1
Zugriffe: 17.687 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +40,58%
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +38,89%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +38,49%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +37,14%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +29,84%
wären schon mal 140 Prozent (seit auf der WL) gewesen.
und wieder merkts keiner.
Nur dieses mal erheblich bessere Voraussetzungen.
Incyte wird wohl keine hunderte Millionen zum Fenster rausschmeissen:
Calithera will have some rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications and will be entitled to receive over $430 million in potential development, regulatory and commercialization milestones from Incyte.
Incyte will fund 70% of global development, Calithera will be responsible for the remaining 30%. Once CB-1158 receives regulatory approvals and is commercialized, Incyte and Calithera will share the profits or losses in the U.S in the ratio of 60% and 40%, respectively. A
Verfolge schon 2 Jahre. Die letzten 2 Monate noch intensiver:
- Tagesumsatz Shares
- Größe der Aktienpakete: da kaufen jetzt ganz andere Anleger. Es dümpelt so vor sich hin den ganzen Tag, dann wird plötzlich ein 50K Paket zu deutlich höherem Kurs aufgekauft. Denke dass jetzt (zumindest überm Teich) CALa das Interesse geweckt hat.
Bin dann mal wieder weg (für längere Zeit)
Nur dieses mal erheblich bessere Voraussetzungen.
Incyte wird wohl keine hunderte Millionen zum Fenster rausschmeissen:
Calithera will have some rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications and will be entitled to receive over $430 million in potential development, regulatory and commercialization milestones from Incyte.
Incyte will fund 70% of global development, Calithera will be responsible for the remaining 30%. Once CB-1158 receives regulatory approvals and is commercialized, Incyte and Calithera will share the profits or losses in the U.S in the ratio of 60% and 40%, respectively. A
Verfolge schon 2 Jahre. Die letzten 2 Monate noch intensiver:
- Tagesumsatz Shares
- Größe der Aktienpakete: da kaufen jetzt ganz andere Anleger. Es dümpelt so vor sich hin den ganzen Tag, dann wird plötzlich ein 50K Paket zu deutlich höherem Kurs aufgekauft. Denke dass jetzt (zumindest überm Teich) CALa das Interesse geweckt hat.
Bin dann mal wieder weg (für längere Zeit)
2 Trades zu je 50.000 Stück
10:52:21§$ 9.45 100
10:52:21§$ 9.40 50,000
10:52:21§$ 9.40 50,000
10:52:21§$ 9.40 14,300
10:52:19§$ 9.50 100
Das meine ich. Da kaufen sich schon längere Zeit einige größer ein bei CAla.
Bin gespannt wo der Kurs am Ende des Jahres ist
10:52:21§$ 9.45 100
10:52:21§$ 9.40 50,000
10:52:21§$ 9.40 50,000
10:52:21§$ 9.40 14,300
10:52:19§$ 9.50 100
Das meine ich. Da kaufen sich schon längere Zeit einige größer ein bei CAla.
Bin gespannt wo der Kurs am Ende des Jahres ist
www.fool.com/investing/2018/02/16/...-inc-rose-as-much-a.aspx
ob hier ein paar cent drin sind.
Kohle haben sie momentan für min 1 Jahr.
Sehe nur ATM welches momentan nicht bedient wird.
As of August 2, 2018, the registrant had 35,987,379 shares of common stock
Second Quarter 2018 and Recent Highlights
• Enrolling Two Randomized Phase 2 Combination Trials of CB-839 in Combination for the Treatment of Renal Cell Carcinoma. The ENTRATA trial, a randomized double-blind placebo-controlled study of late line patients, is enrolling approximately 66 patients to receive either everolimus and CB-839 or everolimus alone. It is now expected to enroll by the fourth quarter of 2018, or early 2019. CANTATA is a randomized double-blind placebo-controlled trial comparing advanced patients treated with cabozantinib and CB-839 to patients treated with cabozantinib alone. This trial will enroll approximately 300 clear cell renal cell carcinoma patients who have previously received one or two prior lines of therapy. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CB-839 in combination with cabozantinib for the treatment of this patient population. The trial opened in 2018 and is expected to take approximately two years to reach the primary endpoint analysis.
•Presented Results of CB-839 in Combination with Capecitabine at the 2018 American Society of Clinical Oncology. A Phase 1 Investigator sponsored clinical trial of CB-839 plus capecitabine was presented at the 2018 American Society of Clinical Oncology (ASCO).1 In patients with late-line colorectal cancer that had progressed on at least one prior fluoropyrimidine-containing regimen, the median PFS was 26 weeks for patients with PIK3CA mutated cancer (n=7) and 16 weeks for patients with PIK3CA wild-type cancer (n=5,p=0.058). The Phase 2 portion of this study in patients with PIK3CA mutant colorectal cancer is ongoing.
•Evaluating CB-839 in Combination with Paclitaxel in Triple Negative Breast Cancer (TNBC). A Phase 2 trial evaluating CB-839 with paclitaxel in TNBC patients is ongoing. Four single arm, open label, cohorts of African American and non-African American patients are being treated in both the early and late stage settings. The primary endpoint of this trial is objective response rate and a number of predictive biomarkers are being assessed. Based on our preliminary Phase 2 clinical trial results and recent changes in the competitive landscape of TNBC, we do not plan to pursue further development of CB-839 plus paclitaxel in TNBC at this time.
• Enrolling INCB001158 Clinical Trials. INCB001158 is being evaluated in multiple clinical trials for the treatment of patients with solid tumors both as a monotherapy, and in combination with immunotherapies and chemotherapy. INCB001158 is being developed as part of a collaboration and license agreement with Incyte.
• Advanced Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis. Arginase has been proposed to be critical in the pathology of cystic fibrosis by impairing production of nitric oxide. CB-280 is an orally administered small molecule inhibitor of arginase. An investigational new drug (IND) application for CB-280 with the U.S. FDA is planned for the first half of 2019.
• Selected CD73 Small Molecule Inhibitor to Enter Clinical Development in 2019. The enzyme CD73 is an oncometabolism target that plays a critical role in the process of ATP conversion to adenosine. An IND application for CB-708, an orally administered small molecule inhibitor of CD73, is planned in 2019.
• R&D Day Planned on October 5, 2018 in New York City. The meeting will focus on the Company’s research and development programs, including CB-280 and CB-708. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website.
Kohle haben sie momentan für min 1 Jahr.
Sehe nur ATM welches momentan nicht bedient wird.
As of August 2, 2018, the registrant had 35,987,379 shares of common stock
Second Quarter 2018 and Recent Highlights
• Enrolling Two Randomized Phase 2 Combination Trials of CB-839 in Combination for the Treatment of Renal Cell Carcinoma. The ENTRATA trial, a randomized double-blind placebo-controlled study of late line patients, is enrolling approximately 66 patients to receive either everolimus and CB-839 or everolimus alone. It is now expected to enroll by the fourth quarter of 2018, or early 2019. CANTATA is a randomized double-blind placebo-controlled trial comparing advanced patients treated with cabozantinib and CB-839 to patients treated with cabozantinib alone. This trial will enroll approximately 300 clear cell renal cell carcinoma patients who have previously received one or two prior lines of therapy. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CB-839 in combination with cabozantinib for the treatment of this patient population. The trial opened in 2018 and is expected to take approximately two years to reach the primary endpoint analysis.
•Presented Results of CB-839 in Combination with Capecitabine at the 2018 American Society of Clinical Oncology. A Phase 1 Investigator sponsored clinical trial of CB-839 plus capecitabine was presented at the 2018 American Society of Clinical Oncology (ASCO).1 In patients with late-line colorectal cancer that had progressed on at least one prior fluoropyrimidine-containing regimen, the median PFS was 26 weeks for patients with PIK3CA mutated cancer (n=7) and 16 weeks for patients with PIK3CA wild-type cancer (n=5,p=0.058). The Phase 2 portion of this study in patients with PIK3CA mutant colorectal cancer is ongoing.
•Evaluating CB-839 in Combination with Paclitaxel in Triple Negative Breast Cancer (TNBC). A Phase 2 trial evaluating CB-839 with paclitaxel in TNBC patients is ongoing. Four single arm, open label, cohorts of African American and non-African American patients are being treated in both the early and late stage settings. The primary endpoint of this trial is objective response rate and a number of predictive biomarkers are being assessed. Based on our preliminary Phase 2 clinical trial results and recent changes in the competitive landscape of TNBC, we do not plan to pursue further development of CB-839 plus paclitaxel in TNBC at this time.
• Enrolling INCB001158 Clinical Trials. INCB001158 is being evaluated in multiple clinical trials for the treatment of patients with solid tumors both as a monotherapy, and in combination with immunotherapies and chemotherapy. INCB001158 is being developed as part of a collaboration and license agreement with Incyte.
• Advanced Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis. Arginase has been proposed to be critical in the pathology of cystic fibrosis by impairing production of nitric oxide. CB-280 is an orally administered small molecule inhibitor of arginase. An investigational new drug (IND) application for CB-280 with the U.S. FDA is planned for the first half of 2019.
• Selected CD73 Small Molecule Inhibitor to Enter Clinical Development in 2019. The enzyme CD73 is an oncometabolism target that plays a critical role in the process of ATP conversion to adenosine. An IND application for CB-708, an orally administered small molecule inhibitor of CD73, is planned in 2019.
• R&D Day Planned on October 5, 2018 in New York City. The meeting will focus on the Company’s research and development programs, including CB-280 and CB-708. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website.
das die Studie nicht für den A... ist.
The Phase 2 portion of this study in patients with PIK3CA mutant colorectal cancer is ongoing.
The Phase 2 portion of this study in patients with PIK3CA mutant colorectal cancer is ongoing.
ir.calithera.com/static-files/...c-88f5-4333-97ed-346752d57cee
Gute Cashausstattung. MK nicht mehr ganz billig. Sind aber wieder gut zurück gekommen.
Gute Cashausstattung. MK nicht mehr ganz billig. Sind aber wieder gut zurück gekommen.
- ca 25 Mio Burn/Q
- Cash 138 Mio 31.3 + 33 Mio über KE im April (also keine kurzfristige KE zu erwarten)
- keine Schulden
-Partnerschaft mit Pfizer mit Meilensteinzahlungen bei entsprechenden Endpunkten
- ENTRATA-Studie hat primären Endpunkt erreicht
- CANTATA-Zulassungsstudie rekrutiert
- Fast Track
-Topline-Ergebnisse werden in 4Q2020 erwartet
- Breites Potenzial in verschiedenen onkologischen Indikationen
- Studie mit NRF2/Keap1-Patienten mit nicht-kleinzelligem Lungenkrebs geplant
- Cash 138 Mio 31.3 + 33 Mio über KE im April (also keine kurzfristige KE zu erwarten)
- keine Schulden
-Partnerschaft mit Pfizer mit Meilensteinzahlungen bei entsprechenden Endpunkten
- ENTRATA-Studie hat primären Endpunkt erreicht
- CANTATA-Zulassungsstudie rekrutiert
- Fast Track
-Topline-Ergebnisse werden in 4Q2020 erwartet
- Breites Potenzial in verschiedenen onkologischen Indikationen
- Studie mit NRF2/Keap1-Patienten mit nicht-kleinzelligem Lungenkrebs geplant
70,5 Mio shares outstanding
50 Mio Share werden von Instis gehalten , Insider , allen voran BVF haben in den letzten 3 Monaten verkauft, also wohl derzeit Seller dran, was zu den günstigen Kursen führt.
4 Analystenratings von den üblichen Bekannten
H C WAINWRIGHT
JEFFERIES & CO.
SVB LEERINK LLC
WILLIAM BLAIR
Liegen alle zwischen 9,5-10. Persönlich gebe ich auf die Ratings im Biobereich nicht viel.
Die Partnerschaft mit Pfizer ist für mich der interessanteste Part
50 Mio Share werden von Instis gehalten , Insider , allen voran BVF haben in den letzten 3 Monaten verkauft, also wohl derzeit Seller dran, was zu den günstigen Kursen führt.
4 Analystenratings von den üblichen Bekannten
H C WAINWRIGHT
JEFFERIES & CO.
SVB LEERINK LLC
WILLIAM BLAIR
Liegen alle zwischen 9,5-10. Persönlich gebe ich auf die Ratings im Biobereich nicht viel.
Die Partnerschaft mit Pfizer ist für mich der interessanteste Part
wird die Pipeline derzeit mit ca. 215 Mio bewertet. Darin sind die Milestones von Pfizer noch nicht inkludiert. Für mich sehr attraktiv. Sehe da noch Potential nach oben.
Mucoviszidose p1b
de.advfn.com/p.php?pid=nmona&article=82840676
de.advfn.com/p.php?pid=nmona&article=82840676
Phase 2 telaglenastat verfehlt den primären Endpunkt
www.fiercebiotech.com/biotech/...2-cancer-trial-axes-35-staff
endpts.com/...rug-calithera-lays-off-a-third-of-its-staffers/
- Cash 138 Mio. $
- CB ca. 22-23 Mio. $
- MK 182 Mio. $
www.fool.com/investing/2021/01/04/...stock-is-plunging-today/
- kein Umsatz
- Verlust 23 Mio. $
- Cash 115 Mio. $
- MK 164 Mio. $
ir.calithera.com/news-releases/...urth-quarter-2020-financial
Zahlen für Q1/21
- keine Umsätze
- Verlust 20 Mio. $
- Cash 103 Mio. $
- MK 138 Mio. $
ir.calithera.com/news-releases/...irst-quarter-2021-financial
Phase-2-Studie KEAPSAKE wird aufgrund eines fehlenden klinischen Nutzens, in der Zwischenanalyse beendet
- die verfügbaren Daten zur Wirksamkeit zeigten keinen klinischen Nutzen, und die Analyse der Daten kam zu dem Schluss, dass die Wahrscheinlichkeit für ein positives Ergebnis der Studie sehr gering ist
ir.calithera.com/news-releases/...cision-discontinue-keapsake
|
Neueste Beiträge aus dem Calithera Bioscienes Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 58 | Calithera Biosciences Reboundkanditat? | Balu4u | Vassago | 03.02.23 13:47 |
